Merck Goes Two For Three In The Big Easy
This article was originally published in The Pink Sheet Daily
The company is refining its arguments in Vioxx cases, though unpredictable juries remain a concern.
You may also be interested in...
New Orleans federal court judge overturns a jury decision awarding $51 mil. in damages in a Vioxx liability suit, calling the amount "excessive."
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.